Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Finland's Lappeenranta-Lahti University of Technology is to build two new test facilities at its nuclear engineering ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.